Hyperlipidemia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517538
  • Report
  • 173 pages
  • P&S Market Research
1 of 3
Hyperlipidemia Therapeutics Pipeline in 2018

Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of hyperlipidemia are being developed to be administered by the oral route, which is convenient to take, and has been considered as non-invasive, often safer route that requires no special training to the patients.

Hyperlipidemia Therapeutics Pipeline is Driven by High Unmet Need

Hyperlipidemia increases cardiovascular risks and lowering elevated Low-Density Lipoprotein-Cholesterol (LDL-C) remains a significant unmet need. Statins are the standard of care available for patients with hypercholesterolemia and are highly effective at lowering LDL-C, with well-documented benefits. However, it is unable to achieve a permanent treatment care for all subset of patients.

A significant subset of patients is unable to tolerate statins due to adverse events, including muscle pain or weakness, increased glucose levels, and in rare and extreme cases, muscle breakdown, kidney failure, and death. Additionally, patients with Heterozygous Familial Hypercholesterolemia (HeFH) or Atherosclerotic Cardiovascular Disease (ASCVD) who require additional LDL-C lowering on top of maximally tolerated statin therapy represent a high-risk patient population with an important unmet medical need.

Hyperlipidemia Therapeutics Pipeline Involves Drug Candidates with Novel Target

It has been observed that most of the companies are developing drug candidates that involves novel target. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, Inclisiran is under the Phase III stage of development by The Medicines Company for the treatment of hyperlipidemia. The drug candidate is an RNAi that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) protein and RNA interference. It was found that Inclisiran cause sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.

Similarly, LY3015014 is under the Phase II stage of development by Eli Lilly and Company that target PCSK9 protein inhibitor. DCR-PCSK9 is a Pre-Clinical drug candidate of Dicerna Pharmaceuticals Inc.

Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Symptoms
4.1.2 Diagnosis
4.1.3 Etiology of Hyperlipidemia
4.1.4 Treatment
4.1.5 Epidemiology
4.2 Key Drivers
4.2.1 Unhealthy Lifestyle
4.2.2 Advancements in Technologies
4.3 Key Barriers
4.3.1 Safety Concerns
4.4 Hyperlipidemia Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. Hyperlipidemia Therapeutics Pipeline Analysis by Phase (2018)
5.1 Filed
5.1.1 CJ-30056
5.1.2 X
5.1.2.1 Clinical trials
5.2 Phase III
5.2.1 CJ30060
5.2.1.1 Clinical trials
5.2.2 X
5.2.3 X
5.2.3.1 Clinical trials
5.2.4 X
5.2.4.1 Clinical trials
5.2.5 X
5.2.5.1 Pre-Clinical studies
5.2.5.2 Clinical trials
5.2.5.3 Clinical results
5.2.5.4 Strategic developments
5.2.5.5 Patent
5.2.6 X
5.2.6.1 Clinical trials
5.2.7 X
5.2.7.1 Clinical trials
5.2.7.2 Clinical results
5.2.7.3 Strategic development
5.2.8 X
5.2.8.1 Clinical trials
5.2.8.2 Clinical trials
5.2.8.3 Strategic development
5.2.9 X
5.2.9.1 Clinical trials
5.2.10 X
5.2.10.1 Clinical trials
5.2.10.2 Strategic developments
5.2.11 X
5.2.11.1 Clinical trials
5.2.12 X
5.2.12.1 Clinical trials
5.2.13 X
5.2.14 X
5.2.14.1 Clinical trials
5.3 Phase II
5.3.1 MGL-3196
5.3.1.1 Clinical trials
5.3.1.2 Clinical results
5.3.1.3 Strategic developments
5.3.2 X
5.3.2.1 Clinical trials
5.3.2.2 Strategic development:
5.3.2.3 Technology
5.3.3 X
5.3.3.1 Clinical trials
5.3.3.2 Strategic developments
5.3.3.3 Technology
5.3.4 X
5.3.4.1 Clinical trials
5.3.5 X
5.3.5.1 Clinical trials
5.3.6 X
5.3.6.1 Pre-Clinical studies
5.3.6.2 Clinical trials
5.3.6.3 Clinical results
5.3.6.4 Strategic developments
5.3.6.5 Designation
5.3.7 X
5.3.7.1 Clinical trials
5.3.7.2 Strategic developments
5.3.8 X
5.3.8.1 Clinical trials
5.3.8.2 Clinical results
5.3.9 X
5.3.9.1 Clinical trials
5.3.9.2 Clinical results
5.3.9.3 Strategic developments
5.3.10 X
5.3.10.1 Clinical trials
5.3.10.2 Clinical trials
5.3.11 X
5.3.11.1 Clinical trials
5.3.11.2 Clinical results
5.3.11.3 Strategic developments
5.3.12 X
5.3.12.1 Clinical trials
5.3.12.2 Strategic developments
5.3.13 X
5.3.13.1 Clinical trials
5.3.13.2 Clinical results
5.3.13.3 Strategic developments
5.4 Phase I/II
5.4.1 RGX 501
5.4.1.1 Pre-Clinical studies
5.4.1.2 Clinical trials
5.4.2 X
5.4.2.1 Clinical trials
5.5 Phase I
5.5.1 CKD 330
5.5.2 X
5.5.3 X
5.5.4 X
5.5.5 X
5.5.6 X
5.5.7 X
5.5.8 X
5.5.9 X
5.5.10 X
5.6 Pre-Clinical
5.6.1 ARO-APOC3
5.6.1.1 Strategic developments
5.6.1.2 Technology
5.6.2 X
5.6.2.1 Strategic developments
5.6.2.2 Technology
5.6.3 X
5.6.4 X
5.6.4.1 Strategic developments
5.6.4.2 Technology
5.6.5 X
5.6.5.1 Technology:
5.6.5.2 Patent
5.6.6 X
5.6.7 X
5.6.8 X
5.6.8.1 Technology
5.7 Discovery
5.7.1 Research Programme: Incrementally Modified Drug
5.7.1.1 Technology
5.7.2 X
5.7.2.1 Technology
5.7.3 X
5.8 Unknown Phase
5.8.1 X

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Player Benchmarking
7.2 SWOT Analysis
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Eli Lilly & Company
8.1.1 Business Overview
8.1.2 Product Offerings
8.2 Merck & Co. Inc.
8.2.1 Business Overview
8.2.2 Product Offerings
8.3 Company 3.
8.3.1 Business overview
8.3.2 Product offerings
8.4 Company 4.
8.4.1 Business Overview
8.4.2 Product Offerings
8.5 Company 5.
8.5.1 Business Overview
8.5.2 Product Offerings
8.6 Company 6
8.6.1 Business overview
8.6.2 Product offerings
8.7 Company 7.
8.7.1 Business overview
8.7.2 Product and service offerings
8.8 Company 8.
8.8.1 Business overview
8.8.2 Product offerings

9. Appendix
9.1 Abbreviations
9.1 Related Reports

List of Tables
Table 1: Types and Causes of Hyperlipidemia
Table 2: Secondary Causes of Hyperlipidemia
Table 3: Pipeline Analysis of Hyperlipidemia Therapeutics, by Company (2018)
Table 4: Description of Cj-30056
Table 5: Description of X
Table 6: Clinical Trials of X
Table 7: Description of Cj30060
Table 8: Clinical Trials of Cj-30060
Table 9: Description of X
Table 10: Description of X
Table 11: Clinical Trials of X
Table 12: Description of X
Table 13: Clinical Trials of X
Table 14: Description of X
Table 15: Clinical Trials of X
Table 16: Description of X
Table 17: Clinical Trials of X
Table 18: Description of X
Table 19: Clinical Trials of X
Table 20: Description of X
Table 21: Clinical Trials of X
Table 22: Description of X
Table 23: Clinical Trials of X
Table 24: Description of X
Table 25: Clinical Trials of X
Table 26: Description of X
Table 27: Clinical Trials of X
Table 28: Description of X
Table 29: Clinical Trials of X
Table 30: Description of X
Table 31: Description of X
Table 32: Clinical Trials of X
Table 33: Description of Mgl-3196
Table 34: Clinical Trials of Mgl-3196
Table 35: Table: Clinical Summary of Mgl-3196
Table 36: Description of X
Table 37: Clinical Trials of X
Table 38: Description of X
Table 39: Clinical Trials of X
Table 40: Description of X
Table 41: Clinical Trials of X
Table 42: Description of X
Table 43: Clinical Trials of X
Table 44: Description of X
Table 45: Clinical Trials of X
Table 46: Description of X
Table 47: Clinical Trials of X
Table 48: Description of X
Table 49: Clinical Trials of X
Table 50: Description of X
Table 51: Clinical Trials of X
Table 52: Description of X
Table 53: Clinical Trials of X
Table 54: Description of X
Table 55: Clinical Trials of X
Table 56: Description of X
Table 57: Clinical Trials of X
Table 58: Description of X
Table 59: Clinical Trials of X
Table 60: Description of Rgx 501
Table 61: Description of X
Table 62: Clinical Trials of X
Table 63: Description of Ckd 330
Table 64: Description of X
Table 65: Description of X
Table 66: Description of X
Table 67: Description of X
Table 68: Description of X
Table 69: Description of X
Table 70: Description of X
Table 71: Description of X
Table 72: Description of X
Table 73: Description of Aro-Apoc3
Table 74: Description of X
Table 75: Description of X
Table 76: Description of X
Table 77: Description of X
Table 78: Description of X
Table 79: Description of X
Table 80: Description of X
Table 81: Description of Research Programme: Incrementally Modified Drug
Table 82: Description of X
Table 83: Description of X
Table 84: Description of X
Table 85: Eli Lilly & Company - At a Glance
Table 86: Merck & Co. Inc. - At a Glance
Table 87: Company 3 - At a Glance
Table 88: Company 4 - At a Glance
Table 89: Company 5 - At a Glance
Table 90: Company 6 - At a Glance
Table 91: Company 7 - At a Glance
Table 92: Company 8 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Split of Primary and Secondary Research
Fig 3: Breakdown of Primary Research Respondents, by Industry Participants
Fig 4: Breakdown of Primary Research Respondents, by Company Type
Fig 5: Hyperlipidemia Drug Candidates Under Development (2018)
Fig 6: Hyperlipidemia Pipeline Split, by Molecule Type (2018)
Fig 7: Hyperlipidemia Therapeutics Pipeline-Split, by Route of Administration (2018)
Fig 8: Breakdown of Clinical Trials, by Region
Fig 9: Breakdown of Clinical Trials, by Trial Status
Fig 10: Key Player Benchmarking
Fig 11: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll